leadf
logo-loader
viewTRACON Pharmaceuticals

TRACON Pharmaceuticals strengthens its cash position in 3Q to fund operations into 2022

The company had cash and cash equivalents of $26.5 million at September 30, 2020, up from $16.4 million at the end of 2019

TRACON Pharmaceuticals -
TRACON Pharmaceuticals says it expects its current funding to sustain operations into the first quarter of 2022

TRACON Pharmaceuticals (NASDAQ:TCON) Tuesday announced that it has ended its third quarter 2020 with cash and cash equivalents of $26.5 million at September 30, 2020, up from $16.4 million at the end of 2019.

The company says it expects its current funding to sustain operations into the first quarter of 2022, following approximately $10 million in private placement equity financings and pre-funded warrants at market from multiple healthcare focused institutional investors in August 2020.

TRACON Pharmaceuticals CEO Charles Theuer said in a statement: “We made great progress during the quarter by securing capital from dedicated healthcare funds that extends our runway past expected ENVASARC registration trial interim data and into 2022. We expect to enroll patients at multiple sites in the ENVASARC trial this year and also expect our partners to submit envafolimab for approval in China before the end of the year.”

He added: “We are focused on enrolling the ENVASARC trial expeditiously so we may deliver interim data in 2021, final data in 2022, and assuming positive clinical data and regulatory approval, potentially commercialize envafolimab in 2023 and thereby address a high unmet need within sarcoma.”

READ: TRACON Pharmaceuticals driving the development of targeted therapies for cancer

Key expected milestones for TRACON going forward include:

  • enrolling patients at multiple sites into the ENVASARC registration trial during the fourth quarter of 2020; 
  • the submission of envafolimab for approval in MSI-H/dMMR CRC to the National Medicinal Products Administration (NMPA) in China by its corporate partners 3D Medicines and Alphamab Oncology; 
  • Independent Data Monitoring Committee review of ENVASARC safety data in 1H 2021;
  • an FDA decision on orphan drug designation for envafolimab in sarcoma in 1H 2021 and;
  • interim ENVASARC efficacy and safety data in mid-2021

TRACON is developing targeted therapies for cancer utilizing a CRO independent, product development platform. The company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC253, a Phase 3 ready small molecule drug candidate for the treatment of prostate cancer; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors.

Contact Sean at sean@proactiveinvestors.com

Quick facts: TRACON Pharmaceuticals

Price: 9.17 USD

NASDAQ:TCON
Market: NASDAQ
Market Cap: $133.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of TRACON Pharmaceuticals named herein, including the promotion by the Company of TRACON Pharmaceuticals in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

TRACON's partners submit new drug application for approval of envafolimab to...

TRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer tells Proactive its corporate partners, Alphamab Oncology and 3D Medicines, have submitted a new drug application for the approval of envafolimab in the indication of MSI-H/dMMR cancer to the National Medical Products Administration in...

on 11/19/2020

2 min read